Overview

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Status:
Completed
Trial end date:
2021-10-29
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma